This site is intended for healthcare professionals only

Diabetes &
Primary Care

Issue:

Vol:25 | No:01

Share this article

+ Add to reading list - Remove from my list

↓ Download pdf

Need to know guide: SGLT2 inhibitors: Indications, doses and licences in adults

Pam Brown

A printable guide to SGLT2 inhibitors, organised by drug and by indication.

Save, Share, Print Article

Share this article

+ Add to reading list – Remove from reading list

↓ Download pdf

In this latest rapid-reference memory aid from Diabetes & Primary Care, Pam Brown summarises the doses, indications and licences of the SGLT2 inhibitor class of diabetes drugs in adults.

Update history

19 October 2023: Updated to reflect changes in licensing for empagliflozin.

Need to know, Newer therapies

Diabetes &
Primary Care

Need to know guide: SGLT2 inhibitors: Indications, doses and licences in adults

Update history

Editorial: What should we do when presented with a very high HbA1c?

Scottish Government and NHS Scotland consensus statement on GLP-1-based therapies for obesity

How to: Rescue therapy in the management of type 2 diabetes

Case report: Non-overweight/non-obese type 2 diabetes

Welcome to the new PCDS Chair and Secretary

Conference over coffee: New medicines, goals of triple therapy, AI prescribing, hypoglycaemia and lipids

Conference over coffee: Diabetes and obesity initiatives, multiple long-term condition management and the bookends of pregnancy